MedPath

UNIVERSITY OF MANCHESTER

🇬🇧United Kingdom
Ownership
-
Established
2004-01-01
Employees
-
Market Cap
-
Website
https://manchester.ac.uk

Clinical Trials

191

Active:11
Completed:98

Trial Phases

5 Phases

Phase 1:7
Phase 2:5
Phase 3:3
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials

Not Applicable
115 (86.5%)
Phase 1
7 (5.3%)
Phase 2
5 (3.8%)
Phase 3
3 (2.3%)
Phase 4
3 (2.3%)

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

Not Applicable
Not yet recruiting
Conditions
Hypertrophic Obstructive Cardiomyopathy \(HOCM\)
Left Ventricular Outflow Tract Obstruction
Myocardial Ischaemia
Interventions
Drug: Camzyos (Mavacamten)
First Posted Date
2025-08-13
Last Posted Date
2025-08-13
Lead Sponsor
University of Manchester
Target Recruit Count
75
Registration Number
NCT07120776
Locations
🇬🇧

Manchester University NHS Foundation Trust, Manchester, United Kingdom

Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care

Not Applicable
Not yet recruiting
Conditions
Increased Reporting of Safety Concerns in Healthcare Settings
First Posted Date
2025-07-24
Last Posted Date
2025-07-24
Lead Sponsor
University of Manchester
Target Recruit Count
10000
Registration Number
NCT07084090

Low Calorie Sweeteners Effects on Appetite

Not Applicable
Completed
Conditions
Appetite
First Posted Date
2025-06-13
Last Posted Date
2025-06-13
Lead Sponsor
University of Manchester
Target Recruit Count
17
Registration Number
NCT07018921
Locations
🇬🇧

University of Manchester, Manchester, United Kingdom

Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis

Not yet recruiting
Conditions
Respiration Disorders
Respiratory Failure
Sepsis
Infection in ICU
Pneumonia
First Posted Date
2025-05-18
Last Posted Date
2025-05-18
Lead Sponsor
University of Manchester
Target Recruit Count
119
Registration Number
NCT06977165
Locations
🇬🇧

The University of Manchester, Manchester, Lancashire, United Kingdom

Validation of Sensors for Long-term Non-Invasive Fetal Monitoring

Not Applicable
Recruiting
Conditions
Fetal Distress With Antenatal Problem
Fetal Growth Retardation
First Posted Date
2025-05-01
Last Posted Date
2025-05-01
Lead Sponsor
University of Manchester
Target Recruit Count
69
Registration Number
NCT06952777
Locations
🇬🇧

Manchester University NHS Foundation Trust, Manchester, United Kingdom

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 38
  • Next

News

AeroRx Therapeutics Reports Positive Phase 2a Results for First Nebulized LABA/LAMA Combination Therapy AERO-007 in COPD

AeroRx Therapeutics announced positive Phase 2a proof-of-concept results for AERO-007, the first nebulized LABA/LAMA combination therapy in development for COPD maintenance treatment.

Weight Gain Combined with Delayed Motherhood Nearly Triples Breast Cancer Risk, Study Finds

New research reveals women who gain significant weight after age 20 and delay childbirth until after 30 (or remain childless) face a 2.7 times higher risk of developing breast cancer.

Weight Loss Injections Show Promising Anti-Cancer Effects Beyond Weight Reduction

Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction.

Advancements in Gene Therapy Approaches for Neuromuscular Diseases: Promises and Challenges

Gene therapy is transforming treatment for neuromuscular diseases, with AAV-mediated approaches offering multiple strategies including adding, silencing, or editing genes depending on disease mechanisms.

Procalcitonin-Guided Protocol Shortens Antibiotic Use in Sepsis Treatment

A UK trial demonstrates that a procalcitonin (PCT)-guided protocol can safely reduce antibiotic duration in sepsis patients by 10% compared to standard care.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.